Financings in Brief: Qmed
This article was originally published in The Gray Sheet
Executive SummaryQmed: Raises $2.5 mil. from private investors. Proceeds will go toward the "operation and marketing" of the Laurence Harbor, New Jersey-based firm's ohms/cad, coronary artery disease management system for use by managed care organizations and large medical group practices. The device is offered by Qmed's Interactive Heart Management Corp. subsidiary...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.